Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months -March 26, 2024 at 08:31 am EDT : vimarsana.com

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months -March 26, 2024 at 08:31 am EDT

JERUSALEM, March 26, 2024 -- Entera Bio Ltd. , a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research announced on March...

Related Keywords

Jerusalem , Israel General , Israel , United States , American , Miranda Toledano , Laura Calvi , Instagram , Facebook , Nasdaq , Entera Bio Ltd , Twitter , American Society For Bone , Linkedin , Drug Administration , National Institutes Of Health , Centers For Disease , Mineral Research , Globenewswire Inc , Biomarkers Consortium , American Society , Regulatory Endpoint , Century Cures , Disease Control , Quality Project , Private Securities Litigation Reform Act , Statements Regarding Forward Looking , Financial Condition , Annual Report , Quarterly Reports , Current Reports , Surrogate Endpoint , Future Trials , Anti Osteoporosis Drugs , Bio Email , Markets ,